Zelira Therapeutics (ASX: ZLD) (OTCQB: ZLDAF) shares are soaring 219% today as the company releases test results on the ZLT-L-007 cannabis derived drug for treatment of diabetic nerve pain. The trumpeting is that this outperformed the “Big Pharma” drug, Lyrica. All of which is great, of course, but there are a couple of further points to be made.
Firstly, this is still very early days. For the results of this test are, as Zelira says, simply to: “These compelling outcomes provide confidence to evaluate the further progression of ZLT-L-007 into formal FDA clinical trials “ That is, this is not a trial that leads to formal approval at all. It's a trial that leads to it being worth starting the process of formal approval. Of course, passing this pre-test is better than not passing it but it is still considerably early days. We can also run the result around the other way - to gain FDA approval you need not only safety and efficacy (does it work?) proof, you also need efficiency (does it work better than other approved drugs?) and that's the important part of what has been shown.
It is a good result but it is still early days.

Zelira Therapeutics share price from ASX
We can also take this as a more general proof of the value of cannabis derived formulations (cannabidoid, or cannabidiol) to treat pain and other issues (glaucoma is a promising avenue of research for example). We all know that dope, marijuana, has interesting effects upon human beings. But being able to slice out the beneficial effects, to medical proof standards, has been proving difficult. Not aided by the manner in which much research in this area was illegal until recent years. So, it might well be that other researchers in the same area will find other applications of use.
But we're about stock markets here so let's talk money. Zelira seems to have losses of about $12 million (in those small AUD dollars) a year. It also has about $3 million in cash and trade receivables. It needs more money that is. True, it raised $8 million in February, after that balance sheet date, but it will still need more than that to pay for FDA testing. That's fine, at this level pharmaceutical research is done on shareholder capital. But what that means is that we think - we think at least - that Zelira is going to be coming asking for some more shareholder capital real soon now.
That's just the way the sector works. Pass a testing milestone and the share price rises. That's just the right time to issue more shares to gain the capital to pay to try passing the next milestone. We would therefore expect there to be something of a natural cap on this current ZLD share price move - that likely new capital raise that we'd suggest is right around the corner.



